Applied Therapeutics News Releases

Applied Therapeutics Reports Second Quarter 2023 Financial Results

Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govo…

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Pre-NDA Meeting to be held with FDA this summer to discuss potential NDA submission for govorestat (AT-007) for treatment of Classic Galactosemia EMA Marketing Authorization Application for govorestat for the treatment of Classic Galactosemia planned i…

Applied Therapeutics Reports First Quarter 2023 Financial Results

Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement of Equity Phase 3 INSPIRE Trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF…

AT-007-1005 Clinical Study

Please fill out the form below to view information about AT-007, e.g. a list of contraindicated medications.